No Data
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlook
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ADC Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ADC Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 79.78% HC Wainwright & Co. $9 → $8 Maintains Buy 04/15/2024 102.25% HC Wainwright & Co. → $9 Re
Express News | ADC Therapeutics SA : H.c. Wainwright Cuts Target Price to $8 From $9
ADC Therapeutics Ltd's Business At Risk: The Perils of Limited Control in Clinical Trials
ECsnap : What platform is this?
TrytosaveabitOP ECsnap: WB!
Jaguar8 : Grrr sometimes late
TrytosaveabitOP Jaguar8: Grrr! BENF also! Why??? Hehehe
Jaguar8 TrytosaveabitOP: Please don’t remind me it will make me cry
View more comments...